Research programme: skin disorders regenerative therapeutics - NuGene

Drug Profile

Research programme: skin disorders regenerative therapeutics - NuGene

Latest Information Update: 13 May 2015

Price : $50

At a glance

  • Originator NuGene International
  • Developer NuGene BioPharma; NuGene International
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Collagen stimulants; Growth stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Burn infections; Burns
  • Research Acne; Scars; Wounds

Most Recent Events

  • 04 May 2015 Early research in Scars in USA (Topical)
  • 04 May 2015 Early research in Wounds in USA (Topical)
  • 04 May 2015 NuGene files for patent protection with US PTO for Burns, Scars, Wound healing bandages treated with nanoencapsulated human adipose derived stem cell culture in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top